Compare Amgen, Inc. (AMGN) vs Carparts.Com Inc (PRTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Carparts.Com Inc — how do they compare? Amgen, Inc. trades at $356.92 (market cap $196.12B), while Carparts.Com Inc trades at $5.76 (market cap $47.94M). The key difference: Amgen, Inc. is far larger — about 4090.9× Carparts.Com Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Carparts.Com Inc pays none. Which is the better fit depends on your goals.
| AMGN | PRTS | |
|---|---|---|
Market Cap | $196.12B | $47.94M |
Sector | Health | Consumer Cyclical |
52-Week High | $388.16 | $11.40 |
52-Week Low | $271.18 | $3.88 |
Enterprise Value | $241.41B | $62.92M |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
PRTS trades at $5.87, down 1.92% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported a net loss of $50.44 million in 2025, though recent quarters have beaten EPS estimates. A recent reverse stock split and new credit facility aim to stabilize operations amid declining revenue trends from $676 million in 2023 to $548 million in 2025.
The outlook remains challenging with persistent losses and negative cash flow, but analyst consensus is positive with 60% buy ratings. Key risks include sustained unprofitability and competitive pressures, while potential upside hinges on cost control and execution of strategic initiatives to return to growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Carparts.Com Inc
CarParts.com Inc is an online provider of automotive aftermarket parts and repair information. The company principally sells its products to individual consumers through its network of websites and online marketplaces. The company's products consist of collision parts serving the body repair market, engine parts to serve the replacement parts market, and performance parts and accessories.
Read more on PRTS →
